Loading
A phase 1/2 trial of Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab in non-Hodgkin lymphoma, run by BeOne Medicines, now recruiting.
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT06634589 by BeOne Medicines, with 80 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-12-02. Interventions recorded: Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, Obinutuzumab, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Glofitamab, Obinutuzumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/